Showing 683 results
-
Media Release /- Kisqali plus fulvestrant demonstrated superior efficacy, with a median PFS of 20.5 months vs. 12.8 months for fulvestrant alone, among overall study population of first- and second-line…
-
Media Release /
-
Media Release /- Promacta receives FDA Priority Review for first-line treatment of SAA based on data showing 52% complete response rate and 85% overall response rate when added to standard immunosuppressive therapy…
-
Media Release /
-
Media Release /- Overall summary score was also significantly higher for Entresto patients than for patients not taking Entresto, as measured by the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12)1-…
-
Media Release /
-
Media Release /- Migraine is a severe neurologic disease that profoundly impacts millions of patients in the United States- Aimovig is the first and only FDA-approved treatment to block the calcitonin gene-related…
-
Media Release /
-
Media Release /- Results from the Kisqali® MONALEESA clinical trial program, the largest industry-sponsored Phase III registration program researching a CDK4/6 inhibitor in HR+/HER2- advanced breast cancer, will be…
-
Media Release /The new product joins the #1 doctor recommended Systane family of dry eye drops as the brand's most advanced solution to dateAlcon launches multimedia campaign to reach the 30 million people living…
